Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibalizumab plus OBR in MDR HIV-1
NCT02475629Phase 3Completed
- Sponsor
- TaiMed Biologics
- Start
- Aug 2015
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of ibalizumab in human immunodeficiency virus infection (HIV), sponsored by TaiMed Biologics. Started Aug 2015; status: completed.
02
Drugs
ibalizumab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02475629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475629.